REP 2139

Drug Profile

REP 2139

Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator REPLICor
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 01 Aug 2016 REPLICor initiates enrolment in its long term follow-up trial of REP 301 for Hepatitis B treatment and Hepatitis D (Combination therapy) in Moldova (NCT02876419)
  • 16 Nov 2015 Interim efficacy data from the phase II REP 301 trial in Hepatitis B infection and Hepatitis D infection presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2015)
  • 09 Nov 2015 REPLICor receives patent allowance for methods of combination therapy using immunotherapeutic agents and agents that lower serum HBsAg in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top